Fisher Wallace
Growth Stage
Medical Devices for Mood and Sleep
Overview
Raised: $526,201
Total Commitments ($USD)
Platform
Dealmaker Securities
Start Date
11/02/2023
Close Date
11/22/2023
Min. Goal
$9,990
Max. Goal
$999,980
Min. Investment
$989
Security Type
Equity - Common
Series
Series B
SEC Filing Type
RegCF
Price Per Share
$10.99
Pre-Money Valuation
$102,170,000
Rolling Commitments ($USD)
Status
Funded
Reporting Date
11/30/2023
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$26,310
# of Investors
369
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2019
Industry
Fitness & Wellness
Tech Sector
Medtech
Distribution Model
B2C
Margin
High
Capital Intensity
High
Fisher Wallace, with a valuation of $102.2 million, is raising funds on Dealmaker Securities. The company manufactures and sells wearable medical devices for mood and sleep disorders, including insomnia, anxiety, and depression. Fisher Wallace’s most recent product, OAK, works as a super device for depression and positions its patent-pending technology as the most rapid treatment for depression. The company has generated $40 million in lifetime revenue through selling 100,000 units and has 14,000 prescribers. Kelly Roman and Charles Fisher founded Fisher Wallace in August 2019. The current crowdfunding campaign has a minimum target of $9,989.91 and a maximum target of $999,980.10. The campaign proceeds will be used for clinical research, regulatory affairs, manufacturing, product development, and operations.
Summary Profit and Loss Statement
| FY 2022 | FY 2021 | |
|---|---|---|
|
Revenue |
$4,739,387 |
$4,230,290 |
|
COGS |
$1,096,113 |
$623,703 |
|
Tax |
$0 |
$250 |
| ||
| ||
|
Net Income |
$-7,073,744 |
$-3,262,291 |
Summary Balance Sheet
| FY 2022 | FY 2021 | |
|---|---|---|
|
Cash |
$128,229 |
$1,929,380 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$439,495 |
$1,999,403 |
|
Short-Term Debt |
$427,470 |
$471,468 |
|
Long-Term Debt |
$1,083,664 |
$576,525 |
|
Total Liabilities |
$1,511,134 |
$1,047,993 |
Financials as of: 11/02/2023
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Fisher Wallace | 11/22/2023 | Dealmaker Securities | $102,170,000 | $526,201 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 10/04/2023 | StartEngine | $100,280,000 | $493,354 | Equity - Common | Funded | RegA+ |
| Fisher Wallace | 02/20/2023 | StartEngine | $81,567,588 | $1,281,201 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 09/01/2022 | StartEngine | $81,236,323 | $357,719 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 05/27/2022 | StartEngine | $80,048,889 | $1,279,724 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 10/26/2021 | StartEngine | $40,000,000 | $5,010,683 | Equity - Common | Funded | RegA+ |
| Fisher Wallace Laboratories | 03/09/2020 | StartEngine | $15,000,000 | $1,056,480 | Equity - Common | Funded | RegCF |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.